Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Increases By 108.1%

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a large increase in short interest in March. As of March 31st, there was short interest totaling 54,960 shares, an increase of 108.1% from the March 15th total of 26,405 shares. Based on an average trading volume of 75,363 shares, the short-interest ratio is presently 0.7 days. Approximately 1.6% of the shares of the stock are short sold.

Revelation Biosciences Stock Up 1.7%

Shares of Revelation Biosciences stock traded up $0.02 during mid-day trading on Monday, hitting $1.19. The stock had a trading volume of 23,812 shares, compared to its average volume of 593,939. The firm has a 50-day moving average of $1.33 and a two-hundred day moving average of $3.14. Revelation Biosciences has a 12-month low of $1.06 and a 12-month high of $44.16. The firm has a market cap of $4.43 million, a P/E ratio of -0.02 and a beta of -0.17.

Revelation Biosciences (NASDAQ:REVB) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.24). Sell-side analysts expect that Revelation Biosciences will post -49.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Revelation Biosciences in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Revelation Biosciences

Several large investors have recently made changes to their positions in the stock. Armistice Capital LLC lifted its holdings in shares of Revelation Biosciences by 442.8% in the 4th quarter. Armistice Capital LLC now owns 434,272 shares of the company’s stock worth $347,000 after acquiring an additional 354,272 shares during the last quarter. Sabby Management LLC lifted its holdings in shares of Revelation Biosciences by 192.5% in the 4th quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock worth $484,000 after acquiring an additional 398,651 shares during the last quarter. Finally, Geode Capital Management LLC acquired a new position in shares of Revelation Biosciences in the 4th quarter worth approximately $27,000. 12.80% of the stock is currently owned by institutional investors and hedge funds.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.